Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


Misregulation of the epidermal growth factor receptor (EGFR) gene is a common theme in cancer biology and consistent efforts have been made to identify the underlying mutations driving tumorigenesis. However some forms of cancer retain one normal copy of EGFR, suggesting the existence of a more general physiological trigger for EGFR aberrant activation. A recent study, presented during this year meeting of the American association for cancer research (AACR), in Philadelphia, showed promising results for a new compound called TH-4000 that is activated upon shortage of oxygen and stably inhibits EGFR activity reducing tumor growth in lung cancer models.

Read more

Breast cancer accounts for one quarter of all cancer cases, resulting in over half a million deaths worldwide per year. Fifteen to twenty percent of all breast cancer diagnoses belong to the HER2 positive subtype. Only about one-third of these patients respond well to standard therapy. But even patients that initially respond eventually develop resistance. Using HER2 positive human breast cancer cell lines, researchers at the University of North Carolina discovered one of the mechanisms underpinning drug resistance in breast cancer and found a way to prevent it from occurring.

Read more

The ability of the immune system to detect cancer cells as foreign bodies is a longstanding concept known as immunosurveillance. This hypothesis has cyclically met the enthusiasm and skepticism of the scientific community because of the high toxicity of some immunotherapies. We are now beginning to understand that the immune system can be trained to specifically attack cancer cells with only minimal effects for the normal surrounding tissues. Scientists at the Washington University School of Medicine in St. Louis have recently published their results from the "First-in-People" clinical trial suggesting that a personalized anti-melanoma vaccine is possible and can elicit a powerful immune...

Read more

Diabetic retinopathy is a diabetic complication consisting in damage to the blood vessels in the retina that, if left untreated, can lead to blindness. The FDA has added diabetic retinopathy in patients with diabetic macular edema to the list of approved indications for aflibercept (Eylea®)

Read more